Tuesday broker round-up
26th Feb 2019 13:32
(Sharecast News) - BT: Berenberg downgrades to hold with a target price of 260p.
Read moreAstraZeneca's Lynparza shows positive results in pancreatic cancer trial
26th Feb 2019 09:29
(Sharecast News) - AstraZeneca has reported positive results from a phase 3 trial of the Lynparza drug, which met the primary endpoint in a study for metastatic pancreatic cancer.
Read morePharma firms to testify in Congress over drug pricing
26th Feb 2019 08:31
(Sharecast News) - Top executives of pharmaceutical companies are set to testify in front of the Senate Finance Committee on Tuesday as part of an investigation into drug pricing in the US.
Read moreAstraZeneca's Brilinta reaches primary endpoint in phase 3 trial
25th Feb 2019 07:29
(Sharecast News) - AstraZeneca announced on Monday that its phase 3 'THEMIS' trial has met its primary endpoint, and demonstrated that 'Brilinta' (ticagrelor) - when taken in conjunction with aspirin - showed a statistically-significant reduction in a composite of major adverse cardiovascular events (MACE) compared to aspirin alone.
Read moreThursday broker round-up
14th Feb 2019 13:11
(Sharecast News) - AVEVA: Numis downgrades to add with a target price of 3,300p.
Read moreAstraZeneca beats forecasts as new drug sales soar
14th Feb 2019 07:45
(Sharecast News) - AstraZeneca reported a strong fourth quarter, beating market expectations for revenues and earnings, with the drugs colossus guiding to another strong year ahead.
Read moreFDA grants AstraZeneca's Fasenra orphan drug designation
6th Feb 2019 09:04
(Sharecast News) - AstraZeneca said on Wednesday that the US Food and Drug Administration has granted orphan drug designation (ODD) to Fasenra for the treatment of hypereosinophilic syndrome (HES), a group of rare and potentially fatal disorders that can cause progressive damage to any organ in the body.
Read moreAstraZeneca oral diabetes treatment gets European marketing approval
1st Feb 2019 15:02
(Sharecast News) - AstraZeneca said on Friday that the European Medicines Agency (EMA) has recommended marketing authorisation for its Forxiga treatment for use as an oral adjunct treatment to insulin in adults with type-1 diabetes.
Read moreFriday broker round-up
25th Jan 2019 13:21
(Sharecast News) - Fresnillo: UBS upgrades to buy with a target price of 1,100p.
Read moreMonday broker round-up
14th Jan 2019 13:44
(Sharecast News) - Next: Credit Suisse downgrades to underperform with a target price of 4,800p.
Read moreAstraZeneca announces structural changes, hires Jose Baselga
7th Jan 2019 16:04
(Sharecast News) - AstraZeneca announced a number of organisational changes on Monday, which it said would support its "continued scientific innovation" and commercial success in the main therapy areas as it entered a new phase in its strategic development.
Read moreAstraZeneca receives EU approval for Bevespi Aerosphere inhaler
20th Dec 2018 14:01
(Sharecast News) - FTSE 100 pharma giant AstraZeneca said its chronic obstructive pulmonary disease treatment Bevespi Aerosphere was approved for use in the EU.
Read moreAstraZeneca upbeat on positive results from three drug trials
20th Dec 2018 07:25
(Sharecast News) - AstraZeneca announced a slew of positive drug trial results on Thursday, first reporting that the Phase III OLYMPUS and ROCKIES trials for roxadustat had each met their primary efficacy endpoints, for the treatment of patients with anaemia in chronic kidney disease (CKD) that were either non-dialysis-dependent or dialysis-dependent, respectively.
Read moreAstraZeneca gets China approval for roxadustat
18th Dec 2018 11:15
(Sharecast News) - AstraZeneca's roxadustat drug has been approved in China for the treatment of anaemia in chronic kidney disease patients on dialysis.
Read moreAstraZeneca's Imfinzi fails to reach endpoint in difficult trial
7th Dec 2018 07:24
(Sharecast News) - AstraZeneca and its global biologics research and development arm MedImmune announced overall survival results for the Phase III EAGLE trial of Imfinzi (durvalumab) on Friday.
Read more